Trends in Pharmacological Sciences

Article	Citations
More than one route to render tumors resistant to cGAS/STING activation	613
Subscription and Copyright Information	397
Subscription and Copyright Information	236
Subscription and Copyright Information	178
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders	165
Subscription and Copyright Information	153
The N terminus-only function of adhesion GPCRs: emerging concepts	151
IRAK4: potential therapeutic target for airway disease exacerbations	146
Anticancer drugs: How to select small molecule combinations?	135
Subscription and Copyright Information	132
Subscription and Copyright Information	129
Advisory Board and Contents	128
Subscription and Copyright Information	124
Epitope landscape in autoimmune neurological disease and beyond	112
Advisory Board and Contents	104
Atogepant (Qulipta®) for migraine prevention	100
Promoting spliceosome assembly for therapeutic intent	97
Advisory Board and Contents	88
Advisory Board and Contents	86
Paving the way for designing drugs targeting TMEM16A	85
Subscription and Copyright Information	84
Advisory Board and Contents	76
Subscription and Copyright Information	76
Subscription and Copyright Information	75
Subscription and Copyright Information	72

Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs	70
Subscription and Copyright Information	69
Advisory Board and Contents	63
Lenacapavir (Sunlenca®) for the treatment of HIV-1	62
The consequences of particle uptake on immune cells	60
Boosting CAR-T cell therapy through vaccine synergy	58
Subscription and Copyright Information	58
Futibatinib (Lytgobi) for cholangiocarcinoma	57
Key metrics to expanding the pipeline of successful antibody–drug conjugates	57
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	57
Obesity pharmacotherapy: incretin action in the central nervous system	56
Targeting of Potassium Channels in Cardiac Arrhythmias	54
Harnessing associative learning paradigms to optimize drug treatment	54
Channeling Force in the Brain: Mechanosensitive Ion Channels Choreograph Mechanics and Malignancies	54
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	53
Shearing of surface mucin saps tumor cell strength	53
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	51
A novel anticancer pharmacological agent targeting mitochondrial complex I	50
Tackling chronic kidney disease in diabetic patients with finerenone	50
Biologics and cardiac disease: challenges and opportunities	49
Translational adaptation in breast cancer metastasis and emerging therapeutic opportunities	48
RH5 antigenic landscape shapes vaccine and antibody development	47
Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls	47
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	47
Structural asymmetry in FGF23 signaling	47
Spare the pain for your gut Treg cells!	46
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	46
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	46
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display	45
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	45
Potential therapeutic targets for trauma management	44
Muscarinic receptors: from clinic to bench to clinic	44
Subscription and Copyright Information	43
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	43
Chemokine receptor CCR1: new target for asthma therapy	42
Unifying mechanism behind the onset of acquired epilepsy	41
Current clinical translation of microbiome medicines	41
Directions to overcome therapy resistance in cancer	41
Nanotherapeutic-directed approaches to analgesia	39
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	39
Subscription and Copyright Information	39
Targeting natural killer cells to enhance vaccine responses	39
Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges	38
Targeting sensory neuron GPCRs for peripheral neuropathic pain	38
Tackling therapy resistance in cancer	38
Artificial protein coronas: directing nanoparticles to targets	38
Peptides as a therapeutic strategy against Klebsiella pneumoniae	37
Acid-sensing ion channels as potential therapeutic targets	37
Deep mutational scanning for therapeutic antibody engineering	37
Visceral obesity and HFpEF: targets and therapeutic opportunities	36

Emerging autism and Fragile X syndrome treatments	33
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	32
Proteomic approaches advancing targeted protein degradation	32
Casimersen for the treatment of Duchenne muscular dystrophy	32
CRISPR-based therapeutics: current challenges and future applications	31
ER stress in obesity pathogenesis and management	31
Biomarkers and targeted therapy for cancer stem cells	31
Metastatic colorectal cancer: mechanisms and emerging therapeutics	31
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	31
Targeting complement in neurodegeneration: challenges, risks, and strategies	31
Compstatins: the dawn of clinical C3-targeted complement inhibition	30
Emerging targets in lipid metabolism for cancer therapy	29
Direct in vivo CAR T cell engineering	29
Therapeutic inhibition of ferroptosis in neurodegenerative disease	29
Neutrophil extracellular traps in wound healing	27
High-power screening (HPS) empowered by DNA-encoded libraries	27
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	26
Targeting extranuclear histones to alleviate acute and chronic inflammation	26
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	25
Pain Signaling by GPCRs and RTKs	25
HSV-1 as a gene delivery platform for cancer gene therapy	24
Advisory Board and Contents	24
Poison exons: tuning RNA splicing for targeted gene regulation	23
GABA transport goes structural	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
A pharmacological strategy to recapitulate exercise-induced antitumoral immunity	23
Ribosome-directed cancer therapies: the tip of the iceberg?	23
Advisory Board and Contents	22
Cancer drug repurposing in autism spectrum disorder	22
Developing novel antifungals: lessons from G protein-coupled receptors	22
A deep dive into degrader-induced protein-protein interfaces	22
GABAA receptors as targets for treating affective and cognitive symptoms of depression	22
Advancing targeted protein degradation modalities	21
Subscription and Copyright Information	21
Biomaterials, biological molecules, and polymers in developing vaccines	21
Advances in the structural understanding of opioid allostery	21
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	21
Challenges and opportunities associated with rare-variant pharmacogenomics	21
Advisory Board and Contents	21
Subscription and Copyright Information	20
Defeating MYC with drug combinations or dual-targeting drugs	20
Advisory Board and Contents	20
Hedgehog signalling in allograft vasculopathy: a new therapeutic target?	20
Subscription and Copyright Information	19
Advisory Board and Contents	19
Supramolecular nanomedicines through rational design of self-assembling prodrugs	18
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	18
Advances in GPCR-targeted drug development in dermatology	18
Circadian biology to advance therapeutics for mood disorders	18
Advisory Board and Contents	17
Subscription and Copyright Information	17
Subscription and Copyright Information	17
Subscription and Copyright Information	17
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules	17
Model-informed precision dosing in inflammatory bowel diseases	17
Reprogramming RNA processing: an emerging therapeutic landscape	17
Advisory Board and Contents	17
Advisory Board and Contents	17
The 2024 New York City Integrative Structural Biology Symposium	17
Advisory Board and Contents	17
Is the AT-rich DNA of malaria parasites a drug target?	16
Leveraging human microbiomes for disease prediction and treatment	16
The role of NMR in advancing small molecule drug discovery	16
Advisory Board and Contents	16
Structural insights into ligand recognition and activation of angiotensin receptors	15
Digoxin as an emerging therapy in noncardiac diseases	15
Efflux Limits Tumor Drug Delivery Despite Disrupted BBB	15
Functional intersections between extracellular vesicles and oncolytic therapies	15
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets	15
Teaching an old dog new tricks: repurposing β-lactams	15
Giving ERK a jERK from the endosome	15
'Living drugs' target CD70 in advanced renal tumors	14
Engineering T cell memory for antitumor immunity	14
Taming PRMT5–adaptor protein interactions	14
Emerging strategies for beta cell transplantation to treat diabetes	14
A smart hospital-driven approach to precision pharmacovigilance	14
Metabolome-guided genome mining of RiPP natural products	13
Therapeutic targeting of exportin-1 beyond nuclear export	13
Poster presentations and session organization: modern conferences	13
Genetically engineered loaded extracellular vesicles for drug delivery	13

Structural snapshot of a β-arrestin-biased receptor	13
Fezolinetant for menopausal hot flashes and night sweats	13
Lighting the way to tumor destruction	13
A perspective on psychedelic teratogenicity: the utility of zebrafish models	13
Metabolite-sensing GPCRs in rheumatoid arthritis	13
Heterobifunctional small molecules to modulate RNA function	13
Peptide libraries: from epitope mapping to in-depth high-throughput analysis	13
Phenotypic approaches for CNS drugs	13
A novel pharmacological entity toward integrated multimodal immunotherapy	13
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology	13
Recent advancements in vaccine research and development	12
Parvalbumin interneuron cell-to-network plasticity: mechanisms and therapeutic avenues	12
Engineering ACE2 decoy receptors to combat viral escapability	12
Advisory Board and Contents	12
M1 receptor positive allosteric modulators discovery approaches	12
Iron metabolism: pathophysiology and pharmacology	12
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	12
Atypical chemokine receptors: emerging therapeutic targets in cancer	12
Deucravacitinib (Sotyktu™) for plaque psoriasis	12
PANoptosis: a novel target for cardiovascular diseases	12
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	11
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	11
Mutations in muscle-type creatine kinase impact HIV prevention	11
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	11
siRNA drug Leqvio (inclisiran) to lower cholesterol	11
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models	11
Modulation of T cells by tryptophan metabolites in the kynurenine pathway	11
Recent advances in targeting autophagy in cancer	11
Anticancer opportunities at every stage of chemokine function	11
NLRP3 and pyroptosis blockers for treating inflammatory diseases	11
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	10
Context-dependent role of SIRT3 in cancer	10
AI-powered therapeutic target discovery	9
Mining LTR-retrotransposon genes for mRNA delivery	9
Advisory Board and Contents	9
Advisory Board and Contents	9
Subscription and Copyright Information	9
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments	9
Close to a year in TIPS’ saddle – I am optimistic	9
Advisory Board and Contents	9
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	9
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	9
Advisory Board and Contents	9
Partial agonists go molecular	9
Extrasynaptic therapeutic targets in substance use and stress disorders	8
Glymphatic-stagnated edema induced by traumatic brain injury	8
Advisory Board and Contents	8
Protein prenylation in mechanotransduction: implications for disease and therapy	8
Thriving as members of under-represented groups in pharmacology-related careers	8
Targeting stressor-induced dysfunctions in protein–protein interaction networks via epichaperomes	8
Advisory Board and Contents	8
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	8
Subscription and Copyright Information	7
Beyond the NFAT Horizon: From Cyclosporine A-Induced Adverse Skin Effects to Novel Therapeutics	7
Approaches to address bias in letters of recommendation	7
Targeting neurological abnormalities in lysosomal storage diseases	7
Lipoxygenases in chronic liver diseases: current insights and future perspectives	7
Striking a gut–liver balance for the antidiabetic effects of metformin	7
Identifying New Antimigraine Targets: Lessons from Molecular Biology	7
PUS7: a targetable epitranscriptomic regulator of glioblastoma growth	7
CRISPR tiling screen reveals cancer epigenetic ‘Goldilocks’ state	7
Bridging the academia-to-industry gap: organ-on-a-chip platforms for safety and toxicology assessment	7
Dopamine receptor divergence revealed using a common ligand	7
Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins	7
The Prognosis of Arthrofibroses: Prevalence, Clinical Shortcomings, and Future Prospects	7
Small Molecule Drug Discovery for Neglected Tropical Snakebite	7
Microfluidic technologies for drug discovery and development: friend or foe?	7
Potential for targeting small heat shock protein modifications	6
Targeting the STAT3 pathway with STAT3 degraders	6
A quick guide to networking for scientists	6
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	6
Emerging approaches to induce immune tolerance to therapeutic proteins	6
MICUs protect the heart by regulating mitochondrial calcium	6
Tiny but mighty: small molecules as vaccine adjuvants	5
Innovating cancer drug discovery with refined phenotypic screens	5
Advances in inhibitor development targeting the PWWP domain	5
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	5
Nitro-fatty acids: promising agents for the development of new cancer therapeutics	5
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	5
G-Protein Peptidomimetics Stabilize GPCR Active State Conformations	5
Targeting dendritic cells to drive PDAC immunotherapy response	5
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	5
Targeted protein degrader development for cancer: advances, challenges, and opportunities	5
Nanotherapy for human papillomavirus-associated cancers: breakthroughs and challenges	5
Advancing non-destructive analysis of 3D printed medicines	5
VMAT structures reveal exciting targets for drug development	5
Membrane protein production and formulation for drug discovery	5
Tension-induced organelle stress: an emerging target in fibrosis	4
Frontiers in CAR-T cell therapy for autoimmune diseases	4
Cation/proton antiporters: novel structure-driven pharmaceutical opportunities	4
The structure and function of YTHDF epitranscriptomic m6A readers	4
Odorant receptors as potential drug targets	4
Subscription and Copyright Information	4
Targeting TRPM channels for cerebral ischemia–reperfusion injury	4
Mentoring future science leaders to thrive	4